Retatrutide 30mg

Retatrutide (Triple GLP-1/GIP/Glucagon Agonist) – 30 mg Dosage Protocol

Retatrutide is an investigational peptide that acts as a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, offering a comprehensive approach to weight management, appetite regulation, and metabolic enhancement. By combining these pathways, Retatrutide supports reduced caloric intake, increased energy expenditure, and improved glycemic control.

Clinical studies have shown significant body weight reduction and metabolic improvements, with a titration-based approach helping to minimize gastrointestinal side effects commonly associated with incretin-based therapies.

This educational protocol outlines a once-weekly subcutaneous dosing strategy with gradual titration.

---

Reconstitute:
Add 3.0 mL bacteriostatic water → ~10 mg/mL (10,000 mcg/mL) concentration (based on a 30 mg vial)

---

Typical Weekly Protocol (Titration):

• Week 1–4: 0.5 mg once weekly
• Week 5–8: 1 mg once weekly
• Week 9–12: 2 mg once weekly
• Week 13+: 4–6 mg once weekly (as tolerated)

---

Easy Measuring:
At 10 mg/mL,

• 1 unit = 0.01 mL ≈ 100 mcg on a U-100 insulin syringe

Example:

• 0.5 mg dose ≈ 5 units
• 1 mg dose ≈ 10 units
• 2 mg dose ≈ 20 units
• 5 mg dose ≈ 50 units

---

Administration:

• Subcutaneous injection (abdomen, thigh, or upper arm)
• Once weekly, same day each week
• Rotate injection sites

---

Storage:

• Lyophilized: Store at −20 °C (−4 °F)
• After reconstitution: Refrigerate at 2–8 °C (35.6–46.4 °F)
• Protect from light; avoid repeated freeze–thaw cycles

---

Note:
Retatrutide is currently under clinical investigation for obesity and metabolic disorders, showing promising results in fat loss, appetite suppression, and insulin sensitivity improvement. Users may experience mild side effects such as nausea, decreased appetite, or fatigue, especially during dose escalation.